Effects of BNT162b2 Messenger RNA Vaccine and ChAdOx1 Adenovirus Vector Vaccine on Deaths From COVID-19 in Adults Aged ≥70 Years

Jamie Lopez Bernal*, Nick Andrews, Charlotte Gower, Julia Stowe, Elise Tessier, Ruth Simmons, Mary Ramsay

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

We estimated the risk of death from coronavirus disease 2019 in vaccinated compared with unvaccinated patients. The risk of death was reduced 44% after 1 dose of the Pfizer-BioNTech BNT162b2 vaccine, 55% after 1 dose of the Oxford-Astrazeneca ChAdOx1 vaccine, and 69% after 2 doses of the BNT162b2 vaccine. This is above the protection provided against infection.

Original languageEnglish
Pages (from-to)349-351
Number of pages3
JournalClinical Infectious Diseases
Volume78
Issue number2
DOIs
Publication statusPublished - 15 Feb 2024

Bibliographical note

Publisher Copyright:
© The Author(s) 2023. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved.

Fingerprint

Dive into the research topics of 'Effects of BNT162b2 Messenger RNA Vaccine and ChAdOx1 Adenovirus Vector Vaccine on Deaths From COVID-19 in Adults Aged ≥70 Years'. Together they form a unique fingerprint.

Cite this